The European Medicines Agency's Pharmacovigilance Risk Assessment Committee has started a class-wide review of injectable iron-containing medicines after reports raised concerns about hypophosphataemia — abnormally low phosphate levels in the blood — and related bone complications.
The review was announced after the committee's 31 August to 3 September meeting.
Hypophosphataemia and hypophosphataemic osteomalacia are already recognized risks of ferric carboxymaltose, one commonly used intravenous iron product. The new review asks a broader question: whether current risk-minimisation measures are sufficient and whether the concern should be addressed across all injectable iron medicines.
Why phosphate matters
Phosphate is essential for bone mineralization, cellular energy metabolism and multiple biochemical processes.
When phosphate remains too low for long enough, bone mineralization can fail. The resulting condition, osteomalacia, can cause bone pain, muscle weakness and fractures.
This creates a diagnostic problem in patients receiving iron therapy because symptoms such as fatigue and muscle discomfort can overlap with the symptoms of iron deficiency itself.
EMA specifically notes that delayed recognition may occur for this reason.
What triggered the review
According to EMA, the review followed reports that raised concerns about whether current measures adequately reduce the risk associated with ferric carboxymaltose.
Serious cases of hypophosphataemia were reported, some progressing to osteomalacia. Importantly, EMA says some cases occurred after only one or two doses and in people without recognized risk factors.
That observation matters because existing precautions emphasize monitoring in patients receiving high doses, long-term treatment or those with known risk factors.
If clinically important cases occur outside those groups, the present mitigation strategy may not identify everyone at risk.
Why all injectable iron products are included
Ferric carboxymaltose has the best-established association, but EMA says similar cases have also been reported with other injectable iron-containing medicines.
The review therefore covers the class rather than one product alone.
Oral iron is not part of the review. EMA explains that oral preparations deliver much smaller amounts of iron over time and are therefore less likely to produce the same degree of phosphate disturbance.
What PRAC will assess
PRAC will review the risk of hypophosphataemia and related bone disorders across injectable iron products, evaluate how well existing risk-minimisation measures are working and determine whether the findings change the overall benefit-risk balance.
Possible outcomes could include changes to product information, monitoring recommendations or other regulatory measures. No such final action has yet been decided.
That distinction is important: the opening of a safety review is a signal that regulators believe the evidence warrants formal assessment. It is not a conclusion that the medicines should no longer be used.
Why intravenous iron is used
Injectable iron is important in patients whose iron deficiency cannot be adequately corrected with oral treatment, when oral iron cannot be tolerated or when iron stores need to be restored more quickly.
In many such patients, intravenous treatment provides substantial clinical benefit.
The regulatory task is therefore not simply to identify a hazard but to determine how large it is, which products and patients are most affected, and how the risk can be reduced without unnecessarily restricting effective treatment.
What patients should understand
A European regulatory review should not prompt patients to discontinue prescribed iron therapy on their own.
The useful takeaway is that persistent or new bone pain, muscle symptoms or marked fatigue after injectable iron may warrant clinical assessment, particularly when repeated doses are being given. The appropriate evaluation depends on the individual clinical context.
The review may eventually result in updated monitoring advice, but EMA has not yet announced a final recommendation.
Primary source
- European Medicines Agency. Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC), 31 August–3 September 2026. https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-31-august-3-september-2026